Targets › MAGEA3
3 programs from 3 companies in 5 trials: 4 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. (UniProt, P43357)
Open in Phaseline: the race on MAGEA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OSE Immunotherapeutics | OSE2101 peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an | TP53, ERBB2, CEA, MAGEA2, MAGEA3 | Phase 3 | Patients With Non-Small Cell Lung Cancer; Solid Advanced Tumor | Dec 2027 |
| Canadian Cancer Trials Group | MG1MA3 (MG1 Maraba/MAGE-A3) Replication-deficient adenovirus vaccine encoding MAGE-A3 tumor antigen | MAGEA3 | Phase 1 | Advanced/Metastatic Solid Tumours | Dec 2026 |
| PDC*line Pharma SAS | PDC*lung01 Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1, | PRAME, MAGEA3, MAGEA4 | Phase 1 | Non Small Cell Lung Cancer | – |
Advanced/Metastatic Solid Tumours (2) Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1) Non Small Cell Lung Cancer (1)
protein or peptide (1), small molecule (1), mixed (1)
Canadian Cancer Trials Group (1) OSE Immunotherapeutics (1) PDC*line Pharma SAS (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.